Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Latest From AFFiRiS GmbH

Lundbeck Breaks Into MAb Development, Adds To Suite Of Parkinson's Candidates

Denmark's mid-sized biopharma, Lundbeck, has taken another potential Parkinson's disease therapeutic into early clinical studies, the third this year, and this time it's a monoclonal antibody, not a small molecule.

Neurology Research & Development

AZ Partners Parkinson's Compound With Takeda

The deal, worth up to $400m, will see the companies develop an early-stage alpha-synuclein antibody, a hot area of research in Parkinson's disease.

Neurology Companies

Venture Funding Deals, September 2015

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a monthly review of emerging In Vitro Diagnostic, Medical Device, and Pharmaceutical companies that have received venture funding. This month’s column covers deals announced July through August 2015.

BioPharmaceutical Medical Device

Praluent, Repatha: FDA guinea pigs to market trailblazers

Sanofi's and Regeneron Pharmaceuticals' Praluent (alirocumab) and Amgen's Repatha (evolocumab) not only are the guinea pigs for how the FDA will handle the first proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitor applications, but the drugs also are expected to be trailblazers in the marketplace for what's coming behind them – notably Pfizer's bococizumab, which is catching up fast to the two leaders.

See All

Company Information

  • Industry
  • Pharmaceuticals
    • Vaccines
  • Biotechnology
    • Large Molecule
  • Other Names / Subsidiaries
    • AFFiRiS AG